Integra LifeSciences (NASDAQ:IART) Price Target Raised to $18.00

Integra LifeSciences (NASDAQ:IART) had its target price raised by analysts at Wells Fargo & Company from $15.00 to $18.00 in a research report issued on Thursday,Benzinga reports. The firm currently has an “equal weight” rating on the life sciences company’s stock. Wells Fargo & Company‘s price objective would indicate a potential upside of 1.76% from the stock’s current price.

A number of other equities analysts also recently weighed in on the stock. Citigroup restated a “neutral” rating and set a $19.00 target price (up from $16.00) on shares of Integra LifeSciences in a report on Wednesday, July 8th. BMO Capital Markets initiated coverage on shares of Integra LifeSciences in a research note on Wednesday, July 8th. They issued a “market perform” rating and a $19.00 price target for the company. UBS Group assumed coverage on shares of Integra LifeSciences in a research report on Tuesday. They issued a “neutral” rating and a $19.00 price objective for the company. Weiss Ratings upgraded shares of Integra LifeSciences from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, May 13th. Finally, Wall Street Zen cut shares of Integra LifeSciences from a “strong-buy” rating to a “buy” rating in a report on Saturday, July 18th. One equities research analyst has rated the stock with a Buy rating, five have issued a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Reduce” and an average target price of $18.86.

Integra LifeSciences Stock Up 7.3%

Shares of NASDAQ:IART traded up $1.20 during midday trading on Thursday, reaching $17.69. The company had a trading volume of 129,503 shares, compared to its average volume of 901,784. The company has a quick ratio of 1.95, a current ratio of 3.38 and a debt-to-equity ratio of 1.75. The business’s 50 day moving average price is $17.63 and its 200 day moving average price is $13.42. The stock has a market cap of $1.38 billion, a PE ratio of -2.73, a P/E/G ratio of 1.37 and a beta of 1.22. Integra LifeSciences has a 1-year low of $8.70 and a 1-year high of $20.49.

Integra LifeSciences (NASDAQ:IART) last released its earnings results on Wednesday, July 29th. The life sciences company reported $0.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.48 by $0.08. Integra LifeSciences had a positive return on equity of 17.42% and a negative net margin of 30.15%.The business had revenue of $418.76 million for the quarter, compared to analyst estimates of $417.54 million. Integra LifeSciences has set its Q3 2026 guidance at 0.530-0.610 EPS and its FY 2026 guidance at 2.400-2.500 EPS. Research analysts forecast that Integra LifeSciences will post 2.45 EPS for the current fiscal year.

Institutional Investors Weigh In On Integra LifeSciences

Institutional investors have recently made changes to their positions in the company. SG Americas Securities LLC bought a new position in shares of Integra LifeSciences during the fourth quarter worth approximately $4,722,000. Hsbc Holdings PLC bought a new stake in Integra LifeSciences in the 4th quarter valued at $879,000. Tejara Capital Ltd boosted its stake in Integra LifeSciences by 42.6% in the 4th quarter. Tejara Capital Ltd now owns 171,813 shares of the life sciences company’s stock valued at $2,134,000 after purchasing an additional 51,300 shares during the period. Systematic Financial Management LP grew its holdings in Integra LifeSciences by 4.5% in the 4th quarter. Systematic Financial Management LP now owns 1,108,599 shares of the life sciences company’s stock valued at $13,769,000 after buying an additional 48,094 shares in the last quarter. Finally, Walleye Capital LLC grew its holdings in Integra LifeSciences by 202.0% in the 1st quarter. Walleye Capital LLC now owns 218,595 shares of the life sciences company’s stock valued at $2,059,000 after buying an additional 146,203 shares in the last quarter. Institutional investors own 84.78% of the company’s stock.

Trending Headlines about Integra LifeSciences

Here are the key news stories impacting Integra LifeSciences this week:

• Positive Sentiment: Q2 earnings exceeded expectations. Integra reported adjusted earnings of $0.56 per share, above the $0.48 consensus and up from $0.45 a year earlier. Revenue of $418.8 million was slightly ahead of the $417.5 million estimate. Integra LifeSciences Reports Second Quarter 2026 Financial Results
• Positive Sentiment: Technical momentum remains a supporting factor. Zacks identified IART as one of three stocks showing breakout potential, noting that the shares were trading near their 52-week high after passing technical screens. 3 Stocks Showing Breakout Potential Ahead of August
• Neutral Sentiment: UBS initiated research coverage. The new coverage may increase institutional attention, although the available report does not specify UBS’s rating or price target. UBS Group Begins Coverage on Integra LifeSciences
• Negative Sentiment: Forward guidance was generally in line rather than a major upgrade. Integra forecast third-quarter EPS of $0.53–$0.61 and revenue of $410 million–$425 million, compared with consensus of $0.56 and $417.3 million. Full-year EPS guidance of $2.40–$2.50 also brackets the $2.45 consensus, while revenue guidance was approximately $1.7 billion. The lack of a meaningful guidance increase may be weighing on the stock despite the Q2 beat. Integra LifeSciences Q2 2026 Earnings Call Transcript

About Integra LifeSciences

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.